Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sylvie Morgeaux"'
Publikováno v:
Vaccine. 34(28)
In case of a bite by a rabies infected animal, the World Health Organisation recommends a prophylactic treatment including the administration of Human Rabies Immunoglobulins (HRIGs) or highly purified F(ab')2 fragments produced from Equine Rabies Imm
Publikováno v:
Biologicals. 28:67-80
The detection of adventitious retroviruses has always been critical for assessing the safety concerns associated with viral vaccines. Assays for the enzymatic activity of reverse transcriptase (RT) are used as general methods for the detection of bot
Autor:
Corinne Gontier-Jallet, Nathalie Castignolles, Daniel Samain, Sylvie Morgeaux, Pierre Perrin, Didier Betbeder
Publikováno v:
Vaccine. 14:1353-1360
Biovectors (BV) are a new family of protein carriers. They are nanoparticles of polymerized polysaccharides substituted with phosphate residues and surrounded by covalently bound lipid molecules (palmitic acid). The effect of BV was tested on the imm
Autor:
Corinne Jallet, Pierre Perrin, F. Fouque, J.-H. Colle, M. Tino De Franco, Sylvie Morgeaux, Noël Tordo
Publikováno v:
Research in Virology. 147:289-299
Responsiveness of T cells (RTC) was studied in BALB/c mice intramuscularly infected with various lyssaviruses. After infection by this peripheral route, two types of viruses could be classified according to their effects: 1) pathogenic viruses, inclu
Autor:
Chokri Bahloul, Philippe Le Mercier, Sylvie Morgeaux, Hassan Badrane, Beatrice Chambert, Noël Tordo, Pierre Perrin, C Gontier, Anne Kouznetzoff, Nathalie Castignolles, Yves Jacob
Publikováno v:
Annales de l'Institut Pasteur / Actualités. 6:110-124
Decrite depuis toujours, element fondateur de l'Institut Pasteur, la rage reste sous les phares de l'actualite: premier vaccin efficace chez l'homme (1885), premier recombinant infectieux chez les virus a ARN negatif non segmente (1994). Pourtant, el
Publikováno v:
Vaccine. 28(7)
Since many years Afssaps applies the 3R's strategy (replacement, reduction and refinement) for the use of laboratory animal testing in the framework of vaccine batch release. In this context, for Hepatitis A vaccines, a study was carried out to asses
Autor:
Marie-Line Joffret, Pierre Sureau, Pierre Perrin, Daniel Oth, Claude Leclerc, Sylvie Morgeaux, Carlos Zanetti
Publikováno v:
Vaccine. 8:385-389
The present report demonstrates that liposomes increase the interleukin-2 (IL-2) dependent proliferation of cytotoxic T-lymphocyte line (CTLL) cells used for the measurement of IL-2 activity. This effect was better observed with suboptimal doses of I
Publikováno v:
Vaccine. 21(1-2)
Prior to batch release of oral poliovirus vaccines (OPV) for marketing purpose, the World Health Organisation (WHO) and European pharmacopoeia require a monkey neurovirulence test to be performed both by the manufacturer and the relevant National Con
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 28(4)
Prior to the official release of each Hepatitis A vaccine lot to the market, a quality control performed by a National Control Authority requires an in vivo or an in vitro potency assay. At the beginning of our work, no standardised in vitro test com
Autor:
Sylvie Morgeaux, Pierre Perrin
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 23(3)
beta-propiolactone (BPL) is an alkylating agent which reacts with many nucleophilic reagents including nucleic acids and proteins. BPL modifies the structure of nucleic acids after reaction mainly with purine residues (notably guanine). It induces ni